{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T17:31:42Z","timestamp":1762623102779},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2007,8,21]],"date-time":"2007-08-21T00:00:00Z","timestamp":1187654400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1007\/s00520-007-0325-9","type":"journal-article","created":{"date-parts":[[2007,8,20]],"date-time":"2007-08-20T07:24:17Z","timestamp":1187594657000},"page":"477-483","source":"Crossref","is-referenced-by-count":12,"title":["Safety and tolerability of velafermin (CG53135-05) in patients receiving high-dose chemotherapy and autologous peripheral blood stem cell transplant"],"prefix":"10.1007","volume":"16","author":[{"given":"Michael W.","family":"Schuster","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsiporah B.","family":"Shore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John G.","family":"Harpel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"June","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bita","family":"Jalilizeinali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Possley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W.","family":"Gerwien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Hahne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-Di C.","family":"Halvorsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,8,21]]},"reference":[{"issue":"9","key":"325_CR1","first-page":"3454","volume":"9","author":"E Alvarez","year":"2003","unstructured":"Alvarez E, Fey EG, Valax P, Yim Z, Peterson JD, Mesri M et al (2003) Preclinical characterization of CG53135 (FGF-20) in radiation and concomitant chemotherapy\/radiation-induced oral mucositis. Clin Cancer Res 9(9):3454\u20133461","journal-title":"Clin Cancer Res"},{"issue":"2","key":"325_CR2","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3816\/SCT.2005.n.006","volume":"2","author":"E Alvarez","year":"2005","unstructured":"Alvarez E, Gerlach VL, Gerwien RW, Fey EG, Watkins BA, Hahne WF et al (2005) Single-dose prevention or short-term treatment with fibroblast growth factor-20 (CG53135\u201305) reduces the severity and duration of oral mucositis. Support Cancer Ther 2(2):122\u2013127","journal-title":"Support Cancer Ther"},{"issue":"1","key":"325_CR3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/sj.emboj.7600460","volume":"24","author":"MN Chamorro","year":"2005","unstructured":"Chamorro MN, Schwartz DR, Vonica A, Brivanlou AH, Cho KR, Varmus HE (2005) FGF-20 and DKK1 are transcriptional targets of beta-catenin and FGF-20 is implicated in cancer and development. EMBO J 24(1):73\u201384","journal-title":"EMBO J"},{"issue":"4","key":"325_CR4","first-page":"187","volume":"5","author":"J Crawford","year":"1999","unstructured":"Crawford J, Tomita DK, Mazanet R, Glaspy J, Ozer H (1999) Reduction of oral mucositis by filgrastim (r-metHuG-CSF) in patients receiving chemotherapy. Cytokines Cell Mol Ther 5(4):187\u2013193","journal-title":"Cytokines Cell Mol Ther"},{"issue":"2","key":"325_CR5","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.cytogfr.2005.01.007","volume":"16","author":"L Dailey","year":"2005","unstructured":"Dailey L, Ambrosetti D, Mansukhani A, Basilico C (2005) Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev 16(2):233\u2013247","journal-title":"Cytokine Growth Factor Rev"},{"issue":"4","key":"325_CR6","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00520-003-0513-1","volume":"12","author":"LS Elting","year":"2004","unstructured":"Elting LS, Shih YC (2004) The economic burden of supportive care of cancer patients. Support Care Cancer 12(4):219\u2013226","journal-title":"Support Care Cancer"},{"issue":"6","key":"325_CR7","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.leukres.2003.10.021","volume":"28","author":"FJ Giles","year":"2004","unstructured":"Giles FJ, Rodriguez R, Weisdorf D, Wingard JR, Martin PJ, Fleming TR et al (2004) A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. Leuk Res 28(6):559\u2013565","journal-title":"Leuk Res"},{"issue":"7","key":"325_CR8","first-page":"3131","volume":"61","author":"M Jeffers","year":"2001","unstructured":"Jeffers M, Shimkets R, Prayaga S, Boldog F, Yang M, Burgess C et al (2001) Identification of a novel human fibroblast growth factor and characterization of its role in oncogenesis. Cancer Res 61(7):3131\u20133138","journal-title":"Cancer Res"},{"issue":"4","key":"325_CR9","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1053\/gast.2002.36041","volume":"123","author":"M Jeffers","year":"2002","unstructured":"Jeffers M, McDonald WF, Chillakuru RA, Yang M, Nakase H, Deegler LL et al (2002) A novel human fibroblast growth factor treats experimental intestinal inflammation. Gastroenterology 123(4):1151\u20131162","journal-title":"Gastroenterology"},{"issue":"8","key":"325_CR10","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1200\/JCO.2003.10.079","volume":"21","author":"NJ Meropol","year":"2003","unstructured":"Meropol NJ, Somer RA, Gutheil J, Pelley RJ, Modiano MR, Rowinsky EK et al (2003) Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol 21(8):1452\u20131458","journal-title":"J Clin Oncol"},{"issue":"3 Suppl 8","key":"325_CR11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1053\/j.seminoncol.2004.04.006","volume":"31","author":"DE Peterson","year":"2004","unstructured":"Peterson DE, Cariello A (2004) Mucosal damage: a major risk factor for severe complications after cytotoxic therapy. Semin Oncol 31(3 Suppl 8):35\u201344","journal-title":"Semin Oncol"},{"issue":"14S","key":"325_CR12","doi-asserted-by":"crossref","first-page":"8008","DOI":"10.1200\/jco.2004.22.14_suppl.8008","volume":"22","author":"DE Peterson","year":"2004","unstructured":"Peterson DE, Petit RG (2004) Phase III study: AES-14 in patients at risk for mucositis secondary to anthracycline-based chemotherapy. J Clin Oncol 22(14S):8008","journal-title":"J Clin Oncol"},{"issue":"9 Suppl","key":"325_CR13","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1002\/cncr.20163","volume":"100","author":"EB Rubenstein","year":"2004","unstructured":"Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J et al (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100(9 Suppl):2026\u20132046","journal-title":"Cancer"},{"issue":"9 Suppl","key":"325_CR14","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1002\/cncr.20162","volume":"100","author":"ST Sonis","year":"2004","unstructured":"Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M et al (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100(9 Suppl):1995\u20132025","journal-title":"Cancer"},{"issue":"10","key":"325_CR15","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/sj.bmt.1704946","volume":"35","author":"A Spencer","year":"2005","unstructured":"Spencer A, Horvath N, Gibson J Prince HM, Herrmann R, Bashford J et al (2005) Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplant 35(10):971\u2013977","journal-title":"Bone Marrow Transplant"},{"issue":"25","key":"325_CR16","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1056\/NEJMoa040125","volume":"351","author":"R Spielberger","year":"2004","unstructured":"Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351(25):2590\u20132598","journal-title":"N Engl J Med"},{"issue":"5B","key":"325_CR17","first-page":"3263","volume":"24","author":"MA Stokman","year":"2004","unstructured":"Stokman MA, Wachters FM, Koopmans P, Burgerhof JG, Groen HJ, Spijkervet FK et al (2004) Outcome of local application of amifostine (WR-1065) on epirubicin-induced oral mucositis. A phase II study. Anticancer Res 24(5B):3263\u20133267","journal-title":"Anticancer Res"},{"issue":"11","key":"325_CR18","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/sj.bmt.1703757","volume":"30","author":"C Thieblemont","year":"2002","unstructured":"Thieblemont C, Dumontet C, Saad H, Roch N, Bouafia F, Arnaud P et al (2002) Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. Bone Marrow Transplant 30(11):769\u2013775","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"325_CR19","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1046\/j.1365-2141.2000.02202.x","volume":"110","author":"AM Wardley","year":"2000","unstructured":"Wardley AM, Jayson GC, Swindell R, Morgenstern GR, Chang J, Bloor R et al (2000) Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol 110(2):292\u2013299","journal-title":"Br J Haematol"},{"key":"325_CR20","first-page":"15","volume-title":"Handbook for reporting results of cancer treatment","author":"World Health Organization","year":"1979","unstructured":"World Health Organization (1979) Handbook for reporting results of cancer treatment. World Health Organization, Geneva, pp 15\u201322"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-007-0325-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-007-0325-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-007-0325-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T22:01:43Z","timestamp":1559080903000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-007-0325-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,21]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["325"],"URL":"https:\/\/doi.org\/10.1007\/s00520-007-0325-9","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,21]]}}}